| 12.53 0.29 (2.37%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.27 |
1-year : | 16.17 |
| Resists | First : | 13.08 |
Second : | 13.85 |
| Pivot price | 12.52  |
|||
| Supports | First : | 11.83 |
Second : | 9.84 |
| MAs | MA(5) : | 12.35 |
MA(20) : | 12.59 |
| MA(100) : | 10.48 |
MA(250) : | 9.31 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 30 |
D(3) : | 25.8 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 13.85 | Low : | 5.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCUL ] has closed below upper band by 49.3%. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.98 - 13.04 | 13.04 - 13.08 |
| Low: | 11.99 - 12.05 | 12.05 - 12.11 |
| Close: | 12.42 - 12.52 | 12.52 - 12.61 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Wed, 24 Sep 2025
Chardan Capital Initiates Ocular Therapeutix (OCUL) With a Buy Rating - Yahoo
Tue, 23 Sep 2025
Voya Investment Management LLC Reduces Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Mon, 22 Sep 2025
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 5% - Here's Why - MarketBeat
Tue, 16 Sep 2025
Ocular Therapeutix's (OCUL) Investor Day to Spotlight AXPAXLI Program's Potential in Retinal Disease Treatment - Sahm
Mon, 15 Sep 2025
Chardan Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq
Mon, 08 Sep 2025
Ocular Therapeutix™ to Host Investor Day on September 30, 2025 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 174 (M) |
| Shares Float | 145 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 90.8 (%) |
| Shares Short | 13,840 (K) |
| Shares Short P.Month | 12,830 (K) |
| EPS | -1.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.76 |
| Profit Margin | 0 % |
| Operating Margin | -502.6 % |
| Return on Assets (ttm) | -31.2 % |
| Return on Equity (ttm) | -63.5 % |
| Qtrly Rev. Growth | -18.2 % |
| Gross Profit (p.s.) | -0.7 |
| Sales Per Share | 0.32 |
| EBITDA (p.s.) | -1.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -176 (M) |
| Levered Free Cash Flow | -115 (M) |
| PE Ratio | -9.95 |
| PEG Ratio | 0 |
| Price to Book value | 7.07 |
| Price to Sales | 38.47 |
| Price to Cash Flow | -12.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|